Managing side effects of anxiolytics

Primary Psychiatry

Volumn 14, Issue 7, 2007, Pages 68-76

  Choy, Yujuan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CALCIUM CHANNEL BLOCKING AGENT; CHLORDIAZEPOXIDE; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; ESTAZOLAM; FLURAZEPAM; GABAPENTIN; HALAZEPAM; HYDROXYZINE; HYPNOTIC AGENT; LORAZEPAM; OXAZEPAM; PHENOBARBITAL; PHENYTOIN; PROPRANOLOL; PROTEINASE INHIBITOR; QUAZEPAM; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRIAZOLAM; UNINDEXED DRUG;

AGITATION; AIRWAY RESISTANCE; ANTEROGRADE AMNESIA; ANXIETY; ANXIETY DISORDER; ATAXIA; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BLURRED VISION; BRADYCARDIA; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; COLITIS; CONCENTRATION LOSS; CONFUSION; DELIRIUM; DEPRESSION; DIARRHEA; DIPLOPIA; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EXCITABILITY; EXCITEMENT; FALL RISK; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIP FRACTURE; HOSTILITY; HUMAN; HYPERACTIVITY; HYPOGLYCEMIA; HYPOTENSION; INSOMNIA; IRRITABILITY; MANIA; MEMORY DISORDER; NAUSEA; NERVOUSNESS; NYSTAGMUS; PARESTHESIA; PATIENT COMPLIANCE; PSYCHOEDUCATION; PSYCHOMOTOR DISORDER; RAGE; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TREMOR; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

EID: 34547182305     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Ballenger JC. Benzodiazepines. In: Schatzberg AF. Nemeroff CB, eds. Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998:271-286.
2. Arana GW, Rosenbaum JF. Handbook of Psychiatric Drug Therapy. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2000.
3. Stahl SM. Essential Psychopbarmacology: Neuroscientific Basis and Practical Applications. 2nd ed. Cambridge, MA: Cambridge University Press; 2000.
4. Micromedex Healthcare Series. Physician's Desk Reference. Available at: www.thomsonhc.com. Accessed June 6, 2007.
5. Lader M. Clinical pharmacology of benzodiazepines. Annu Rev Med. 1987;38:19-28.
6. Tanaka E. Clinically significant pharmacokinetic drug interactions with benzodiazepines. J Clin Pharm Ther. Oct 1999;24(5):347-355.
7. Cozza KL, Armstrong SC. Concise Guide to the Cytochrome P450 System. Drug Interaction Principles for Medical Practice. Washington, DC: American Psychiatric Publishing; 2001.
8. Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des. 2002;8(1):45-58.
9. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med. 1993;328(19):1398-1405.
10. Moller HJ, Effectiveness and safety of benzodiazepines. J Clin Psychopharmacol. 1999;19(6 suppl 2):2S-11S.
11. Verster JC, Volkerts ER, Verbaten MN. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study. Neuropsychopharmacology 2002;27(2):260-269.
12. Allain H, Bentue-Ferrer D, Polard E, Akwa Y, Patat A. Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging. 2005;22(9):749-765.
13. Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry. 2005;66(suppl 2):9-13.
14. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18(1):37-48.
15. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol. 2004;19(3):437-454.
16. Stevens JC, Pollack MH. Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents. J Clin Psychiatry. 2005;66(suppl 2):21-27.
17. Smith BD, Salzman C. Do benzodiazepines cause depression? Hosp Community Psychiatry. 1991;42(11):1101-1102.
18. Kravitz HM, Fawcett J, Newman AJ. Alprazolam and depression: a review of risks and benefits. J Clin Psychiatry. 1993;54(suppl):78-84.
19. Olshaker JS, Flanigan J. Flumazenil reversal of lorazepam-induced acute delirium. J Emerg Med. 2003;24(2):181-183.
20. Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006;104(1):21-26.
21. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy. 2004;24(9):1177-1185.
22. Kalachnik JE, Hanzel TE, Sevenich R, Harder SR. Benzodiazepine behavioral side effects: review and implications for individuals with mental retardation. Am J Ment Retard. 2002;107(5):376-410.
23. Rothschild AJ, Shindul-Rothschild, Viguera A, Murray M, Brewster S. Comparison of the frequency of behavioral disinhibition on alprazolam, clonazepam, or no benzodiazepine in hospitalized psychiatric patients. J Clin Psychopharmacol. 2000;20(1):7-11.
24. Rosenbaum JF. Attitudes toward benzodiazepines over the years. J Clin Psychiatry. 2005;66(suppl 2):4-8.
25. Hicks R, Dysken MW, Davis JM, Lesser J, Ripeckyj A, Lazarus L. The pharmacokinetics of psychotropic medication in the elderly: a review. J Clin Psychiatry. 1981;42(10):374-385.
26. Li JM. Pain management in the hospitalized patient. Med Clin North Am. 2002;86(4):771-795.
27. O'Brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66(suppl 2):28-33.
28. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
29. Rickels K, DeMartinis N, Rynn M, Mandos L. Pharmacologic strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol. 1999;19(6 suppl 2):12S-16S.
30. Salzman C. The APA Task Force report on benzodiazepine dependence, toxicity, and abuse. Am J Psychiatry. 1991;148(2):151-152.
31. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65(suppl 5):7-12.
32. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990;47(10):899-907. Erratum in: Arch Gen Psychiatry. 1991;48(1):51.
33. Rickels K, Case WG, Schweizer E, Garcia-Espana F, Fridman R. Benzodiazepine dependence: management of discontinuation. Psychopharmacol Bull. 1990;26(1):63-68.
34. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry. 1990;47(10):908-915.
35. Herman JB, Rosenbaum JF, Brotman AW. The alprazolam to clonazepam switch for the treatment of panic disorder. J Clin Psychopharmacol. 1987;7(3):175-178.
36. Otto MW, Bruce SE, Deckersbach T. Benzodiazepine use, cognitive impairment, and cognitive-behavioral therapy for anxiety disorders: issues in the treatment of a patient in need. J Clin Psychiatry. 2005;66(suppl 2):34-38.
37. Spiegel DA. Psychological strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol. 1999;19(6 suppl 2):17S-22S.
38. DuPont RL. A physician's guide to discontinuing benzodiazepine therapy. West J Med. 1990;152(5):600-603.
39. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry. 1996;153(5):592-606.
40. Weinstock L, Cohen LS, Bailey JW, Blatman R, Rosenbaum JF. Obstetrical and neonatal outcome following clonazepam use during pregnancy: a case series. Psychother Psychosom. 2001;70(3):158-162.
41. Eros E, Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2002;101(2):147-154.
42. Lin AE, Peller AJ, Westgate MN, Houde K, Franz A, Holmes LB. Clonazepam use in pregnancy and the risk of malformations. Birth Defects Res A Clin Mol Teratol. 2004;70(8):534-536.
43. Bonnot O, Vollset SE, Godet PF, d'Amato T, Dalery J, Robert E. In utero exposure to benzodiazepine. Is there a risk for anal atresia with lorazepam? [French]. Encephale. 2003;29(6):553-559.
44. Rickels K. Buspirone in clinical practice. J Clin Psychiatry. 1990;51(suppl):51-54.
45. Jann MW. Buspirone: an update on a unique anxiolytic agent. Pharmacotherapy. 1988;8(2):100-116.
46. Ninan PT, Cole JO, Yonkers KA. Nonbenzodiazepine anxiolytics. In: Schatzberg AF, Nemeroff CB, eds. Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998:287-300.
47. Gelenberg AJ. Buspirone: seven-year update. J Clin Psychiatry. 1994;55(5):222-229.
48. Wheatley D. Buspirone: multicenter efficacy study. J Clin Psychiatry. 1982;43(12 Pt 2):92-94.
49. Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ. Review of the side-effect profile of buspirone. Am J Med. 1986;80(3B):17-21.
50. Rickels K, Weisman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry. 1982;43(12 Pt 2):81-86.
51. Goldberg HL, Finnerty R. Comparison of buspirone in two separate studies. J Clin Psychiatry. 1982;43(12 Pt 2):87-91.
52. Robinson D, Napoliello M, Schenk J. The safety and usefulness of buspirone as an anxiolytic drug in elderly versus young patients. Clin Ther. 1988;10(6):740-746.
53. Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. Am J Med. 1986;80(3B):41-51.
54. Gammans RE, Westrick ML, Shea JP, Mayol RF, LaBudde JA. Pharmacokinetics of buspirone in elderly subjects. J Clin Pharmacol. 1989;29(1):72-78.
55. Noyes R Jr. Beta-adrenergic blocking drugs in anxiety and stress. Psychiatr Clin North Am. 1985;8(1):119-132.
56. Ananth J, Lin KM. Propranolol in psychiatry. Therapeutic uses and side effects. Neuropsychology 1986;15(1):20-27.
57. Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl). 1998;139(4):402-406.
58. Darcis T, Ferreri M, Natens J, Burtin B, Deram P. A multicentre double-blind placebo-controlled study investigating the anxiolytic efficacy of hydroxyzine in patients with generalized anxiety. Hum Psychopharmacol. 1995;10:181-187.
59. Llorca PM, Spadone C, Sol O, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry. 2002;63(11):1020-1027.
60. Simons KJ, Watson WT, Chen XY, Simons FE. Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. Clin Pharmacol Ther. 1989;45(1):9-14.
61. Simons FE, Watson WT, Chen XY, Minuk GY, Simons KJ. The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. J Clin Pharmacol. 1989;29(9):809-815.
62. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999;19(4):341-348.
63. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007;28(2):75-82. Erratum in: Trends Pharmacol Sci. 2007;28(4);151.
64. Beydoun A, Uthman BM, Sackellares JC. Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol. 1995;18(6):469-481.